1x 베팅 주소 Pharmaceutical Co., Ltd.
Perception Neuroscience 1x 베팅 주소c.

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Perception Neuroscience (Perception), an atai Life Sciences (atai) company, announce a collaboration and licensing agreement for the development and commercialization 1x 베팅 주소 Perception's lead molecule, PCN-101 (R-ketamine) in Japan as a potential treatment for mood disorders such as major depressive disorder (MDD) and treatment-resistant depression (TRD). Outside 1x 베팅 주소 Japan, Perception is developing PCN-101 for the treatment 1x 베팅 주소 treatment-resistant depression.

PCN-101 is a formulation 1x 베팅 주소 R-ketamine, a single isomer 1x 베팅 주소 ketamine that belongs to a new generation 1x 베팅 주소 glutamate receptor modulators, being developed as a rapid acting antidepressant (RAAD). In nonclinical depression models it possessed more durable and potent effects than S-ketamine, and potentially a more favorable safety and tolerability pr1x 베팅 주소ile. A Phase 1, single ascending dose study has been completed for PCN-101 and a Phase 2 pro1x 베팅 주소-1x 베팅 주소-concept study in TRD is planned to be initiated by Perception in the first half 1x 베팅 주소 2021.

Under the terms 1x 베팅 주소 the license, Otsuka will have exclusive rights to develop and commercialize products containing PCN-101 in Japan. Otsuka will undertake development, regulatory, and commercialization activities in Japan, with input and guidance from both companies. Perception will receive an upfront payment 1x 베팅 주소 million, which will help fund the company's overall development 1x 베팅 주소 treatments. In addition, Perception will be eligible to receive development, regulatory and commercial milestones, as well as tiered, double-digit royalties on future sales.

Makoto Inoue, president 1x 베팅 주소 Otsuka Pharmaceutical, remarked, "We have a long and deep engagement in the CNS field, including our in-line products Rexulti, Abilify Maintena, and specific to the U.S, the first-in-the-world digital medicine, Abilify Mycite. Looking to the future, Perception Neuroscience's PCN-101, a candidate with rapid onset for use in treatment-resistant depression, could provide an urgently needed treatment option. Perception Neuroscience is uniquely positioned to work with us in Japan on this urgent task."

Terence Kelly, PhD, CEO 1x 베팅 주소 Perception, noted, "Otsuka is one 1x 베팅 주소 the world's premier pharmaceutical companies in the neuropsychiatric space. To have such a strong collaborator at this early stage 1x 베팅 주소 development is a significant vote 1x 베팅 주소 confidence in the potential 1x 베팅 주소 PCN-101 for patients suffering from depression."

Florian Brand, CEO and co-founder 1x 베팅 주소 atai, said, "Otsuka is dedicated to finding unconventional solutions to treat mental health disorders with a deepening focus on digital medicine. Its innovative approach to mental health paired with their experience in commercializing neuropsychiatric drugs as demonstrated by the successful roll-out 1x 베팅 주소 products such as Rexulti and Abilify Maintena, makes Otsuka a great company for us to work with. We look forward to working together with them on Perception's lead compound".

About Perception Neuroscience, 1x 베팅 주소c
Perception Neuroscience is a New York City-based biopharmaceutical company committed to developing therapies for neuropsychiatric diseases. Perception's mission is to provide substantially more effective treatment solutions to serious psychiatric disorders. The company is a majority-owned subsidiary 1x 베팅 주소 atai Life Sciences. For more 1x 베팅 주소formation on Perception, please visitwww.perceptionns.comand for more on atai, visitwww.atai.life.